Efficacy of ruxolitinib for HAVCR2 mutation-associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of haematology"
DOI: 10.1111/bjh.18817
Abstract: Frequent germline mutations of HAVCR2, recently identified in subcutaneous panniculitis-like T-cell lymphoma (SPTCL), are associated with an increased risk of hemophagocytic lymphohistiocytosis (HLH). However, SPTCL-HLH represents a challenge because of the difficulties in treatment with… read more here.
Keywords: hlh; havcr2; efficacy ruxolitinib; hemophagocytic lymphohistiocytosis ... See more keywords